COVID-19: Vaccines and Therapeutics
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will convene July 22 to discuss a pair of recent issues related to COVID-19 vaccines.
Johnson & Johnson was notified that the Food and Drug Administration now will require that the company add to the label of its COVID-19 vaccine a warning of a small, increased risk of Guillain-Barré syndrome, a rare but potentially serious neurological condition.
As summer moves along, the U.S. is marking a pivotal point in the pandemic. A majority of Americans — nearly 55% — now have received one COVID-19 vaccine dose, and 48% are fully vaccinated.
LifePoint Health combines the best of large health system resources and grassroots efforts to vaccinate hundreds of thousands of individuals across its national network.
Photo Credit: Parkland Health & Hospital System
Protecting community members by mitigating the spread of infection and feeling safe in the community were Faye Sheppard’s #MyWhy. Sheppard, a member of the American Society for Health Care Risk Management, an affiliate of the AHA, and vice chair of the Board of Directors for Cuero (Texas) Regional…
Pfizer Inc. will soon seek authorization for a booster dose of its COVID-19 vaccine, the company said, in an attempt to “stay ahead” of the coronavirus and its various mutations
The Commonwealth Fund reported that approximately 279,000 lives have been saved through the U.S.’s vaccination efforts, with 1.25 million avoiding hospitalization.
The Food and Drug Administration July 2 authorized for emergency use one more batch of drug substance for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore.
Photo Credit: Torrance Memorial Medical Center